In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders the following dosage schedule combining parenteral and oral therapy is suggested:
Dexamethasone Sodium Phosphate Injection, 4 mg/mL — First day , 1 or 2 mL (4 or 8 mg) intramuscularly.
Dexamethasone tablets, 0.75 mg — Second and third days , 4 tablets in two divided doses each day; fourth day 2 tablets in two divided doses; fifth and sixth days , 1 tablet each day; seventh day , no treatment; eighth day , follow-up visit.
This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.
Intra-articular, intralesional and soft tissue injections are generally employed when the affected joints or areas are limited to one or two sites. Dosage and frequency of injection varies depending on the condition and the site of injection. The usual dose is from 0.2 to 6 mg. The frequency usually ranges from once every three to five days to once every two to three weeks. Frequent intra-articular injection may result in damage to joint tissues. Some of the usual single doses are:
|Site of Injection||Amount of Dexamethasone Phosphate (mg)|
|Large Joints (e.g., knee)||2 to 4|
|Small Joints (e.g., Interphalangeal, Temporomandibular)||0.8 to 1|
|Bursae||2 to 3|
|Tendon Sheaths||0.4 to 1|
|Soft Tissue Infiltration||2 to 6|
|Ganglia||1 to 2|
Dexamethasone Sodium Phosphate Injection is particularly recommended for use in conjunction with one of the less soluble, longer-acting steroids for intra-articular and soft tissue injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Dexamethasone Sodium Phosphate Injection, USP is available in the following packages:
1 mL vials packaged in 25s (NDC 0641-6145-25)
5 mL vials packaged in 25s (NDC 0641-6146-25)
1 mL vials packaged in 25s (NDC 0641-0367-25)
Protect from light: Keep covered in carton until time of use. Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Avoid freezing. Do not use if solution is hazy or has a precipitate. Do not autoclave.
To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For Product Inquiry call 1-877-845-0689.
*1. Cavanagh, D.; Singh, K. B.: Endotoxin shock in pregnancy and abortion, in: “Corticosteroids in the Treatment of Shock”, Schumer, W.; Nyhus, L. M., Editors, Urbana, University of Illinois Press, 1970, pp. 86-96.
2. Dietzman, R. H.; Ersek, R. A.; Bloch, J. M.; Lillehei, R. C.: High-output, low-resistance, gram-negative septic shock in man, Angiology 20: 691-700, Dec. 1969.
3. Frank, E.: Clinical observations in shock and management (In: Shields, T. F., ed.: Symposium on current concepts and management of shock), J. Maine Med. Ass. 59: 195-200, Oct. 1968.
4. Oaks, W. W.; Cohen, H. E.: Endotoxin shock in the geriatric patient, Geriat. 22: 120-130, Mar. 1967.
5. Schumer, W.; Nyhus, L. M.: Corticosteroid effect on biochemical parameters of human oligemic shock, Arch. Surg. 100: 405-408, Apr. 1970.
A HIKMA COMPANY
Eatontown, NJ 07724 USA
Revised June 2016
10 mg/mL Rx only
(dexamethasone phosphate equivalent)
1 mL Vial
FOR IV OR IM USE ONLY
PROTECT FROM LIGHT
1 Dexamethasone Sodium Phosphate 10 mg, 1 mL
1 Sterile Alcohol Prep Pad
1 Adhesive Bandage
3 Povidone-Iodine Swabsticks
1 Retractable Syringe w/ Needle 23G x 1
Packaged in the USA for:
Reno, NV 89501
Single Use Only
CAUTION: Federal law restricts this device for sale by or on the order of a physician. This package has not been terminally sterilized. Individual items in package can be sterile where indicated by the original manufacturer. Do not sterilize. Store between 59°F – 86°F.
| READYSHARP DEXAMETHASONE |
dexamethasone sodium phosphate injection
|Labeler — Terrain Pharmaceuticals (078358750)|
Revised: 10/2021 Terrain Pharmaceuticals
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.